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Vitamin D and early rheumatoid arthritis
Stephanie R. Harrison1,2, Gurpreet Jutley3, Danyang Li1, Ilfita Sahbudin3,
Andrew Filer3, Martin Hewison1,4 and Karim Raza2,3*
Abstract
Background: Previous studies have linked rheumatoid arthritis (RA) risk and disease activity with vitamin D-deficiency
(low serum 25-hydroxyvitamin D (25OHD)), but a causal role for vitamin D in RA is still unclear, with conflicting results
from many previous studies, partly due to heterogeneity in study design and patient populations. In this study we
aimed to (1) analyse serum 25OHD in early inflammatory arthritis, (2) compare 25OHD with disease activity and fatigue
in early RA and (3) determine whether low 25OHD is associated with progression to RA.
Methods: An analysis of 790 patients recruited to the Birmingham Early Inflammatory Arthritis Cohort and followed
longitudinally to determine clinical outcomes. The following were recorded at baseline: demographic data, duration of
symptoms, duration of early morning stiffness (EMS), tender and swollen joint counts, Visual Analogue Scale (VAS) pain/
fatigue/EMS, PHQ-9, HAQ and FACIT-Fatigue scores, DAS28-ESR, DAS28-CRP, CRP, ESR, anti-CCP antibody status,
rheumatoid factor status, and serum 25OHD (ng/ml). Diagnosis was recorded at 0 and 12months onwards as either
RA, Undifferentiated Inflammatory Arthritis (UIA; synovitis not meeting other classification/diagnostic criteria), Clinically
Suspect Arthralgia (CSA; arthralgia of an inflammatory type without synovitis), or Other.
Results: Baseline demographic data were similar between all groups, with median symptom duration of 16.8–
34.0 days. Baseline 25OHD was not significantly different between groups [median, interquartile range (IQR): RA
46.7, 30.0–73.3; UIA 51.4, 30.0–72.3; CSA 47.7, 30.3–73.0; Other 39.9, 28.6–62.2]. In RA (n = 335), there were no
significant differences between 25OHD and measures of disease activity or fatigue. No association between
25OHD and progression from UIA or CSA to RA was observed.
Conclusions: There was no clear association between serum 25OHD and baseline diagnosis, RA disease activity,
or progression from UIA or CSA to RA. Future studies of other vitamin D metabolites may better define the
complex role of vitamin D in RA.
Keywords: Vitamin D, Inflammation, Rheumatoid arthritis, Psoriatic arthritis, Undifferentiated inflammatory arthritis
Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease characterised by synovitis affecting the small/
medium joints and extra-articular manifestations [1].
Early diagnosis and treatment maximise chances of
inducing remission thereby preventing permanent disab-
ling joint damage [2]. Currently there are few clinical or
biochemical markers to predict who will respond to RA
treatment, and approaches to predicting which patients
with undifferentiated inflammatory arthritis (UIA) or
clinically suspect arthralgia (CSA) will progress to RA
are imperfect [3, 4]. However, recent studies have
suggested that vitamin D status may be a potential con-
tributor to inflammatory disorders such as RA [5]. In
vitro, vitamin D metabolites modulate inflammation
through changes in T helper and regulatory T cell func-
tion [5, 6]. In vivo, vitamin D metabolites including the
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main circulating metabolite 25-hydroxyvitamin D
(25OHD), and the active form of vitamin D 1,25-dihy-
droxyvitamin D (1,25(OH)2D) have been linked to RA
disease progression [7–10], and vitamin D supplementa-
tion may have beneficial effects for patients with estab-
lished RA [11, 12]. What is less clear is the role of
vitamin D status in the onset and early progression of
RA. In 2015, Cooles et al. reported no relationship be-
tween 25OHD and CRP, ESR, symptom duration, tender
joint count (TJC), swollen joint count (SJC), or patients’
global health visual analogue scale (GH-VAS) in a small
cohort of 73 RA patients [13], and similarly Neilen et al.
found no evidence of low vitamin D in blood donor
samples from patients in the pre-RA phase [14]. Con-
versely, other studies have reported an association of
serum 25OHD or 1,25(OH)2D status with some markers
of disease activity in early RA [15, 16].
The aim of the current study was to use a large pro-
spective cohort of early inflammatory arthritis patients
to: (i) compare total serum 25OHD levels between early
inflammatory arthritis patients with different baseline
diagnoses; (ii) explore the relationship between 25OHD
levels and measures of RA disease activity and of fatigue,
and; (iii) determine whether low serum 25OHD is linked
to progression from CSA or UIA to RA.
Methods
We enrolled patients with inflammatory arthritis or CSA
newly seen in rheumatology clinics into the Birmingham
Early Inflammatory Arthritis cohort (BEACON) between
2013 and 2019 from rheumatology outpatient depart-
ments at Sandwell and West Birmingham NHS Trust
and University Hospitals Birmingham NHS Trust.
Demographic information including age, sex, BMI,
smoking status and ethnicity were recorded. In addition,
clinical data including duration of symptoms, early
morning stiffness (EMS), Tender Joint Count (TJC) and
Swollen Joint Count (SJC), DAS28-ESR, DAS28-CRP,
visual analogue scale (VAS) pain, fatigue and EMS,
PHQ9, HAQ and FACIT-Fatigue scores were collected,
alongside CRP, ESR, anti-CCP antibody and RF levels, at
baseline (0 months (M)). Classification criteria for RA
[17] were applied at 0M and at 12M or beyond. In
addition, we looked at two distinct groups of patients
representing different time points in the transition to
RA. Patients with synovitis not meeting criteria for RA
or other rheumatological diseases (i.e. UIA) and
inflammatory-type arthralgia without synovitis (CSA).
Serum 25OHD concentrations were analysed using NHS
laboratory assays and reported as ng/mL.
Box-and-whisker diagrams depicting the median and
interquartile range (IQR) were used to describe non-
parametric variables, and percentages for categorical var-
iables. Significance between groups was determined by
non-parametric testing with either Pearson’s correlation
coefficient, Kruskal-Wallis test and Chi-squared tests as
appropriate, using SPSS v25. Ethical approval was
granted by the NRES Committee West Midlands - The
Black Country (REC 12/WM/0258).
Results
Overall 790 patients were included in the study. Baseline
age, sex, smoking status, BMI and symptom duration are
shown in Table 1. There were significant differences
noted between groups for age and symptom duration
(p < 0.001 for both). The median duration of symptoms
at time of clinic visit was 26 days, however there was sig-
nificant variation (IQR 13.3–54.4). Data on ethnicity
were also recorded; 60.7% of patients considered them-
selves as White British, 20.4% Asian or Asian British
and 7.8% Black or Black British.
We initially compared 25OHD levels between clinical
groups [RA, UIA, CSA and other diagnoses (e.g. psori-
atic arthritis, gout)] at initial clinical presentation to a
Rheumatologist and prior to the commencement of dis-
ease modifying anti-rheumatic drug (DMARD) therapy
for the patient’s arthritis where clinically indicated.
There were no significant differences between groups
(Fig. 1). However, there was a wide distribution of
25OHD values across all groups [median IQR (ng/mL):
RA = 46.7 (30.0–73.0), UIA = 51.5 (30.0–72.7), CSA =
47.7 (30.3–73.0), Other = 39.9 (28.6–62.2)]. Of note, a
significantly higher number of RA patient samples were
taken from March to September (Suppl Table 1), a time
of year when most adults will be able to synthesise vita-
min D from sunlight [18]. In the RA group, those tested
between March and September had on average a higher
baseline vitamin D, although this was not statistically
significant (Suppl Fig. 1, p = 0.165).
Subsequently, we analysed whether serum 25OHD
levels correlated with clinical disease activity measures
and other disease related variables in patients diagnosed
with RA at baseline. 25OHD levels were recorded for
335 of these patients; there were no clear associations
between serum 25OHD levels and baseline EMS dur-
ation, TJC, SJC, DAS28-ESR, DAS28-CRP, VAS pain,
VAS fatigue, VAS EMS, PHQ9, HAQ, FACIT-Fatigue,
CRP or ESR (Table 2).
Finally, we took CSA and UIA patients who had been
enrolled in the study for at least 12M, and compared
baseline serum 25OHD levels in those who progressed
to other diagnoses at 12M with those whose diagnosis
remained unchanged. For the CSA group (n = 150),
follow-up data were not available for 36 patients (24%),
and a further 9 patients did not have vitamin D levels
measured at baseline, leaving 105 patients eligible for in-
clusion in the subgroup analysis. Of these, 60 remained
CSA, 28 progressed to RA, 11 progressed to UIA and 6
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progressed to other forms of inflammatory arthritis.
Baseline vitamin D levels were not significantly different
between groups (p = 0.851, Fig. 2). In the UIA group
(n = 120), follow-up data were not available for 35 pa-
tients (28.9%), and vitamin D data were missing for a
further 4 patients, leaving 81 patients eligible for inclu-
sion in this subgroup analysis. Of these 81 patients, 58
patients remained UIA, 19 progressed to RA and 4 pro-
gressed to other forms of chronic inflammatory arthritis.
Vitamin D levels were not significantly different between
those who remained UIA, and those who progressed to
RA or other diagnoses (p = 0.908, Fig. 3). Importantly, in
the CSA and UIA groups, 25OHD levels at baseline were
not significantly different in those without follow up data
compared with those for whom follow up data were
available (Suppl. Figure 2, p = 0.863).
Some CSA and UIA patients were commenced on
DMARDs (methotrexate, hydroxychloroquine or sulfa-
salazine, alone or in combination) during follow-up if
the treating clinician felt that was appropriate. Progres-
sion of either CSA or UIA to RA may be influenced by
DMARD therapy commenced during the clinical follow
up period as this may reduce rate of progression to RA
in those at risk. Of the CSA patients who remained as
having CSA, only one (baseline vitamin D level 68 ng/
mL) had been commenced on a DMARD. Of the CSA
patients who progressed to RA, eight (baseline vitamin
D level 66.5 ng/mL (48.0–79.5)) had been commenced
on a DMARD before RA development. In the CSA
population, DMARD use during follow-up is thus un-
likely to be a factor limiting transition to RA. Of the
UIA patients who remained UIA, 27 had been com-
menced on a DMARD (baseline vitamin D level 46.9 ng/
mL (28.3–67.0)) while of those who progressed to RA,
14 had been commenced on a DMARD before RA devel-
oped (baseline vitamin D level 50.1 ng/mL (32.0–60.0)). It
is possible that some of the UIA patients on DMARDs
who remained UIA during follow-up may have actually
developed RA had they not commenced a DMARD. How-
ever, of those UIA patients started on a DMARD, there
was no difference in the baseline vitamin D level between
those who progressed to RA and those who did not.
Discussion
This study exploring the relationship between vitamin D
levels and clinical characteristics at presentation and
final clinical diagnoses after follow up is, to our know-
ledge, the first of its kind to be conducted in an early
Table 1 Baseline patient characteristics
All RA UIA CSA Other
No. patients 790 368 139 169 114
Age*, years mean (SD) 52.4 (15.5) 55.5 (15.2) 51.4 (15.4) 46.3 (13.7) 52.3 (16.5)
Missing (no.) n = 0 n = 0 n = 0 n = 0 n = 0
Sex, % female 64.3 68.8 59.0 72.8 43.9
Missing (no.) n = 0 n = 0 n = 0 n = 0 n = 0
Ethnicity,%
White British 60.7 58.2 59.7 60.4 71.1
White Other 4.7 4.6 3.6 6.6 3.5
Asian or Asian British 20.4 20.4 22.3 21.9 15.8
Black or Black British 7.8 9.0 10.8 4.8 5.3
Other 2.7 2.8 2.8 3.6 0.9
Missing or not stated (no.) n = 27 n = 18 n = 1 n = 4 n = 4
Smoking status, %
Current 19.9 20.5 18.7 21.3 18.4
Previous 31.5 29.9 34.5 28.4 37.8
Never 47.2 49.2 45.3 49.7 43.2
Missing (no.) n = 8 n = 2 n = 2 n = 1 n = 3
BMI, kg/m2 mean (SD) 28.7 (6.4) 28.7 (6.5) 28.0 (5.6) 28.9 (7.1) 29.5 (6.1)
Missing (no.) n = 41 n = 24 n = 5 n = 8 n = 4
Symptom duration*,days median (IQR) 26.0 (13.3–54.4) 24.1 (13.0–52.2) 24.1 (13.0–57.0) 34.0 (18.0–70.1) 25.7 (10.5–55.7)
Missing (no.) n = 12 n = 7 n = 1 n = 2 n = 2
C current, CSA clinically suspect arthralgia, N never, no. number of cases, P previous, RA rheumatoid arthritis, SD standard deviation, UIA unclassified
inflammatory arthritis
* denotes statistically significant difference between groups (p < 0.001, Kruskall Wallis test)
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arthritis cohort. Furthermore, we assessed more disease
related variables than previous studies, including
markers relating to fatigue (VAS fatigue and FACIT-
Fatigue scores). Nielen et al. have previously reported
that vitamin D deficiency does not increase risk of pro-
gression to RA in patients at risk on the basis of positive
serology and musculoskeletal symptoms in the absence
of synovitis [14]. Similarly, in our cohort, despite there
being a range of different 25OHD values in all groups,
we did not find any relationship between 25OHD and
clinical variables in early RA and the development of
arthritis/RA in those at risk with CSA/UIA. This latter
finding may be worth further exploration in a larger ad-
equately powered cohort.
The main strengths of this study were the sample size,
which is larger than previous early arthritis cohorts in
which vitamin D has been analysed, and therefore pro-
vides novel insight into vitamin D at this critical time
point in the trajectory of inflammatory joint disease. We
compared serum 25OHD levels with a wide range of clin-
ical and biochemical markers of disease, including both
subjective and objective measures, giving a comprehensive
insight into their relationship with serum 25OHD. Previ-
ous studies have found conflicting results as to whether
there is a relationship between vitamin D levels and
markers of disease activity [19]. Data presented in the
current study strongly suggest that low serum 25OHD is
not linked to any marker of disease activity in early RA.
Furthermore, the inclusion of patients with UIA provides
a novel insight into this facet of arthritis.
There are important limitations to our data. Firstly, al-
though the study had large numbers of patients, there
was significant loss to follow up in all groups at 12
months. This reduced power to detect significant differ-
ences in 25OHD levels between those UIA and CSA pa-
tients who progressed to RA and those who did not
progress to RA. Secondly, a significantly higher number
of RA patient samples were taken from March to Sep-
tember; a time of year when most adults will be able to
synthesise vitamin D from the sunlight [18]. In the RA
group those tested between March and September had
on average a higher baseline vitamin D, although this
was not statistically significant. Nevertheless, this could
have impacted on our ability to detect any relationship
between low 25OHD and markers of RA disease activity.
In addition, we were unable to reliably determine which
patients were receiving vitamin D supplements, and
when they may have begun these in relation to the onset
of their joint symptoms, owing to the frequent (and in-
consistently recorded) use of over-the-counter (OTC)
supplements. GPs are encouraged to recommend OTC
supplements to patients with vitamin D insufficiency
(30-50 nmol/L serum 25OHD) rather than issuing a pre-
scription for vitamin D [18]. Accordingly, GP records
could not be used as a means of determining which pa-
tients were taking vitamin D supplements at baseline.
Many patients do not tell doctors they take vitamin sup-
plements as they do not necessarily consider them medi-
cations, and furthermore, patients are usually unaware
of their preparation’s formulation (vitamin D2 vs D3) or
strength making it impossible to adjust for vitamin D
supplementation use in our analysis.
This study focused on total serum 25OHD concentra-
tions as this is the analysis used in most routine assay
services. However, there are multiple vitamin D metabo-
lites which affect both innate and adaptive immune pro-
cesses at the molecular level, and these have been shown
to play a role in the aetiopathogenesis of RA. Studies
have shown the active form of vitamin D, 1,25(OH)2D,
promotes tolerogenic DC cell function [20, 21], main-
tains the balance of Th1/Th2 cells [22], suppresses the
proinflammatory TH17 phenotype [23–25], and pro-
motes T-regulatory (Treg) cell function [26, 27], whilst
facilitating migration of T cells to the site of inflamma-
tion and phenotype stabilisation [28–30]. Similarly, the
vitamin D receptor (VDR), which plays an important
role in facilitating PBMC responses to 1,25(OH)2D in
immune homeostasis [31], is altered in RA [32] and
VDR polymorphisms are linked to the development of
arthritis [33]. Thus, it is likely that simple measurement
of serum 25OHD provides only a limited perspective on
the potential impact of vitamin D on diseases such as
Fig. 1 Concentrations of serum 25OHD levels across diagnostic groups
where levels were available at baseline. Boxes represent median and
interquartile range (IQR), whiskers represent the range, and beyond this
any extreme outlier values are also shown. Values for each group are as
follows: (i) rheumatoid arthritis (RA), n= 335, median 46.7, IQR 30.0–73.0;
(ii) undifferentiated inflammatory arthritis (UIA), n= 130, median 51.5,
IQR 30.0–72.7; (iii) clinically suspect arthralgia (CSA), n= 156, median
47.7, IQR 30.3–73.0; (iv) other forms of arthritis (Other) n= 102, median
39.9, IQR 28.6–62.2
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RA. Further studies are needed to determine if other
forms of vitamin D are more effective determinants of
its anti-inflammatory action.
The compartment in which vitamin D is measured may
also be important. Serum can be obtained through simple
phlebotomy, but the levels and behaviour of vitamin D and
its metabolites at the site of inflammation, the synovial
joint, may differ relative to peripheral blood. Our group has
reported differences in vitamin D and its metabolites be-
tween serum and synovial fluid in patients with established
RA [34]. Although we did not measure cytokine expression,
evidence from in vitro and murine studies suggests the dif-
ferences inflammatory cytokine milieu in the synovial tissue
compartment will modulate the effects of vitamin D further
[35]. Thus, future studies should focus on analysis of mul-
tiple vitamin D metabolites and their relationship with in-
flammatory factors within specific microenvironment sites
of RA disease. Further research is thus needed to better elu-
cidate the role of vitamin D and its metabolites not only in
the peripheral blood, but at the site of inflammation, the
synovial joint. Understanding how vitamin D changes with,
and as a result of, the inflammatory milieu in the synovial
joint will provide new insights, and potential novel treat-
ment approaches. In recent studies of T cells from RA pa-
tients we observed much stronger responses to 1,25(OH)2D
in T cells from the peripheral blood compared to paired in-
flamed joint synovial fluid from the same patient [36]. This
suggests that once RA disease is established, there is in-
sensitivity to 1,25(OH)2D in immune cells, with this effect
severely limiting the anti-inflammatory benefits of 1,
25(OH)2D. Thus, it is possible that, even in early RA dis-
ease, much higher levels of vitamin D than previously
thought are required to induce beneficial effects on synovial
inflamamtion.
Conclusion
This study did not show any clear associations between
serum 25OHD and baseline diagnosis, in patients with a
range of different inflammatory arthritides, disease activ-
ity in patients with RA, or progression from UIA or CSA
to RA. Our data thus provide further clarity on an issue
where previous studies have yielded conflicting data; that
is, whether RA disease activity is linked to serum vitamin
D levels. Future research should focus on validating
these findings including those related to vitamin D at
baseline and subsequent disease trajectories, in another
cohort powered to detect statistical significance. Further-
more, it will be important to assess different vitamin D
Table 2 Correlations between serum 25OHD concentrations at
baseline and clinical characteristics of RA patients at baseline
No. patients Correlation co-efficient P value
Duration EMS 335 0.074 0.191
ESR 335 −0.045 0.418
CRP 321 −0.015 0.785
TJC68 333 0.075 0.170
SJC66 333 0.029 0.601
TJC28 333 0.077 0.163
SJC28 333 0.017 0.758
VAS Patient global 327 −0.008 0.157
DAS28-ESR 315 0.037 0.513
DAS28-CRP 324 0.047 0.402
VAS pain 319 0.012 0.831
VAS EMS 115 −0.103 0.272
VAS fatigue 319 −0.021 0.713
FACIT fatigue 287 0.005 0.926
HAQ 286 −0.014 0.808
PHQ9 297 −0.006 0.913
CRP C-reactive protein, DAS disease activity score, EMS early morning stiffness,
ESR erythrocyte sedimentation rate, FACIT functional assessment of chronic
illness therapy, HAQ health assessment questionnaire, PHQ patient health
questionnaire, SJC swollen joint count, TJC tender joint count, VAS visual
analogue scale
Fig. 2 Concentrations of serum 25OHD for all CSA patients at
baseline according to final diagnosis after 12 months. Boxes
represent median and interquartile range (IQR), whiskers represent
the range. Values for each group are as follow: (i) Remained CSA,
n = 60, median 47.1, IQR 29.6–68.8; (ii) Progressed to UIA, n = 11,
median 42.0, IQR 28.5–88.5; (iii) Progressed to RA, n = 28, median
51.8, IQR 25.9–76.0; (iv) Progressed to Other; n = 6, median 54.0, IQR
40.8–81.5. There were no statistically significant differences between
groups (p = 0.851)
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metabolites, their carrier proteins, and enzymes involved
in vitamin D metabolism that might affect the local ac-
tion of vitamin D in the joint, to allow a more compre-
hensive understanding of the role of vitamin D in RA
pathogenesis.
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